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Leukocyte Depletion of Random Single-Donor Platelet Transfusions Does 
Not Prevent Secondary Human Leukocyte Antigen-Alloimmunization  
and Refractoriness: A Randomized Prospective Study
By K. Sintnicolaas, M. van Marwijk Kooij, H.C. van Prooijen, B.A. van Dijk, W.L.J. van Putten,
F.H.J. Claas, V.M.J. Novotny, and A. Brand
We studied the value of leukocyte depletion of platelet trans­
fusions for the prevention of secondary human leukocyte 
antigen (HLA)-alloimmunization in patients with a high-risk 
of prior immunization induced by pregnancies. Seventy-five 
female patients with hematologic malignancies (mostly 
acute leukemia) and a history of pregnancy were random­
ized to receive either standard random single-donor platelet 
transfusions (mean leukocytes, 430 x 10s per transfusion) 
or leukocyte-depleted random single-donor platelet transfu­
sions. Leukocyte depletion to less than 5 x 1 0 s leukocytes 
per platelet transfusion (mean leukocytes, 2 x 10° per trans­
fusion) was achieved by filtration. Of the 62 evaluable pa­
tients, refractoriness to random donor platelets occurred in
41% (14 of 34) of the patients in the standard group and in 
29% (8 of 28) of the patients in the filtered group (P = .52); 
anti-HLA antibodies developed in 43% (9 of 21) of individuals 
in the standard group and 44% (11 of 25) of cases in the 
filtered group. The time toward refractoriness and develop­
ment of anti-HLA antibodies was similar for both groups. We 
conclude that leukocyte depletion of random single-donor 
platelet products to less than 5 x 10® per transfusion does 
not reduce the incidence of refractoriness to random donor 
platelet transfusions because of boostering of anti-HLA anti­
bodies.
© 1995 by The American Society of Hematology.
REFRACTORINESS to random donor platelets caused sions containing less than 20 X 106 leukocytes per transfu- by alloimmunization occurs in 30% to 50% of pa­
tients.1'3 The antibodies involved are mostly directed against 
human leukocyte antigens (HLAs). Procedures to provide 
alloimmunized patients with platelets obtained from HLA- 
matched donors4 or alternatively from donors selected by a response occurred that was not prevented by the degree of 
platelet crossmatch5 are logistically complicated, costly, and leukocyte depletion applied, 
still 10% to 30% of these transfusions are unsuccessful/’
sion, it was observed that the incidence o f HLA-alloimmuni- 
zation was not decreased in patients with previous 
pregnancies in contrast with nonpresensitized patients.10 This 
suggests that a secondary (or booster) anti-HLA immune
This explains the interest for developing methods to prevent 
alloimmunization.
Studies both in rats and in mice have shown that pure
It is the aim of the present study to investigate the role 
of more vigorous leukocyte depletion of platelet suspensions, 
ie, less than 5 X 106 leukocytes per transfusion for the pre­
vention of the secondary anti-HLA immune response. There-
platelets do not provoke a primary immune response.7,8 This fore, only females with previous pregnancies were the sub- 
suggests that primary HLA-alloimmunization after platelet jects of a prospective randomized controlled study that was
transfusions is caused by the leukocytes contaminating the 
platelet suspension. A nonrandomized retrospective study in 
humans indeed suggested that leukocyte depletion of platelet 
transfusions reduced the development of HLA-alloimmuni-
conducted in four centers. Random single-donor platelet 
transfusions were used exclusively because it has been docu­
mented that the use of this non-leukocyte-depleted product 
might postpone the development of alloimmunization,13,14
MATERIALS AND METHODS
zation.9 In further randomized and/or prospective studies, especially in patients with previous pregnancies, 
it was confirmed that leukocyte depletion of both platelet 
transfusions and red blood cell (RBC) products resulted in 
a decreased frequency of HLA-alloimmunization,2,3,1<1'11 in 
particular, the incidence of the primary anti-HLA immune 
response.11,12 In a nonrandomized prospective study on the 
value of leukocyte-depleted multiple donor platelet transfu-
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Patients were eligible for entry into the study when they fulfilled 
all of the following criteria: (1) untreated hematologic malignancy; 
(2) history of previous pregnancies; (3) no blood transfusions re­
ceived in the past 6 weeks except for filtered RBCs; and (4) transient 
thrombocytopenia caused by bone marrow (BM) failure. Seventy- 
five patients were randomized and stratified by hospital to receive 
either standard random single-donor platelets (standard group) or 
random single-donor platelets leukocyte depleted by filtration (fil­
tered group). Patients remained on study until one of the following 
events occurred: (1) refractoriness to random single-donor platelets; 
(2) death; or (3) BM transplantation.
Preparation o f  Blood Components and Transfusion Policy
RBC concentrates. Buffy-coat-depleted RBC concentrates were 
filtered within 36 hours after collection through a cellulose acetate 
filter (Cellselect; Nederlands Produktielaboratorium voor Bloedtrans-
charge payment. This article must therefore be hereby marked fusieapparatuur en Infusievloeistoffen BY, Emmer-Compascuum,
“ advertisement” in accordance with 18 U.S.C. section 1734 solely to 
indicate this fact.
© 1995 by The American Society o f Hematology.
0006-4971/95/8503-0217$3.00/0
The Netherlands) in a closed system using a sterile docking device 
(SCD; I-Iaemonetics, Braintree, MA). This procedure results in a 
median number of 0.4 X 10ft leukocytes/U with 99% of units con­
taining less than 5 X  106 leukocytes.15
824 Blood, Vol 85, No 3 (February 1), 1995: pp 824-828
PREVENTION OF SECONDARY HLA-ALLOIMMUNIZATION 825
Table 1. Patient Characteristics
Standard
Group
Filtered
Group
Total no. of evaluable patients 34 28
Mean age (range) 50 (18-74) 50 (33-76)
Diagnosis
ANLL 27 22
ALL 6 2
NHL 1 1
MDS 0 2
MM 0 1
Mean no. of pregnancies (range) 3 (1-9) 3 (1-11)
No. of previously transfused
patients 3 5
Abbreviations: ANLL, acute nonlymphocytic leukemia; ALL, acute 
lymphocytic leukemia; NHL, non-Hodgkin's lymphoma; MDS, myelo- 
dysplastic syndrome; MM, multiple myeloma.
Single-dorior platelet concentrates. Single-donor platelets were 
collected by hemapheresis using discontinuous flow centrifugation 
(Haemonetics, V50, surge-protocol). Patients in the standard group 
received the platelet suspensions without further processing. For the 
preparation of leukocyte-depleted platelet products, platelet suspen­
sions were filtered through a cellulose acetate filter (Cellselect; 
NPBI, Emmer-Compascuum, The Netherlands) designed for filtra­
tion of RBC. This filter has been shown to be efficient for the 
removal of leukocytes from platelet suspensions provided that the 
platelets are inactivated during filtration either by adding ACD-A to 
lower the pH to 6.5 to 6.8, or 12.5 fig prostacylin to the platelet 
suspension before filtration.1'’ Filtration was performed within 36 
hours after collection to reduce the risk of immunization by leuko­
cyte fragments. After filtration, the platelets were transfused immedi­
ately. Standard platelets were also transfused within 36 hours after 
collection. Platelet products were routinely irradiated (20 Gy) in one 
center.
The platelet and leukocyte contents of standard and filtered platelet 
products are shown in Table 1. Platelet and leukocyte counts préfil­
tration were established automatically (different types of analyzers 
per center). Leukocyte counts postfiltration were counted manually 
using a 1/10 dilution o f the blood sample with TUrk Solution and a 
Fuchs Rosenthal chamber. The detection limit of this method is » 5  
x  lO'VL leukocytes, which corresponds to x  H)'1 leukocytes per 
platelet transfusion.
Transfusion regimen. ABO-compatible platelets were transfused 
prophylactically when the platelet count dropped below 10 to 20 X 
10‘VL, or therapeutically for invasive procedures and in case of major 
hemorrhagic symptoms at platelet counts above 10 to 20 X 10’VL. 
No granulocyte transfusions were administered.
Assessment of platelet recovery and definition o f refractori­
ness, Posttransfusion platelet recoveries were performed I hour 
and 16 to 20 hours after the platelet transfusion. Platelet recovery 
was calculated according to the following formula:
Absolute Increment X  Blood Volume
Recovery (%) = 100 X
No. of Transfused Platelets
Blood volume was calculated as body surface area (n r)  X 2.5. 
No correction for splenic pooling was made.
Patients were considered refractory to random single-donor plate­
let transfusions when one of the following occurred: (1) two consecu­
tive platelet transfusions with I-hour posttransfusion platelet recov­
eries of less than 20% in the absence of clinical factors known to
adversely affect platelet recovery (temperature >  38.5°C, septicemia, 
disseminated intravascular coagulation [DfC] or splenomegaly); or 
(2) a single platelet transfusion with 1-hour posttransfusion platelet 
recovery of less than 20% in the presence of anti-HLA antibodies.
Anti-HLA antibody screening. Sera were collected at entry and 
at weekly intervals during a transfusion period and on clinical indica­
tion, ie, in case of poor posttransfusion platelet recoveries. Final 
serum samples were obtained 2 to 4 weeks after the last transfusion. 
Sera were stored at -7Q°C until testing, Each serum was tested in 
the complement-dependent lymphocytotoxicity test17 against a panel 
of 2 1 selected donors covering most of the defined I-1LA-A and HLA- 
B specificities. The screening test was considered positive when at 
least 10% of the panel cells showed cytotoxicity (>50%  dead cells 
per well).
Statistical analysis. The occurrence of clinical refractoriness and 
the development of anti-HLA antibodies were analyzed as a function 
of time and the number of transfusions received using the actuarial 
method of Kaplan-Meijer. The log-rank test was applied to test 
for differences between the two treatment groups. Cox proportional 
hazard model was used to calculate the relative risk of developing 
refractoriness or HLA antibodies in the filtered group as compared 
with the standard group with 95% confidence limits (CLs). The 
Mann-Whitney U test was used to test for differences between the 
percentages panel reactive antibodies of the two groups.
RESULTS
Patients
Thirteen patients were excluded from evaluation because: 
(1) anti-HLA antibodies were present at entry (n = 4); (2) 
less than two transfusions were administered (n =  7); (3) 
administration of blood products other than filtered RBCs 
in the period of 6 weeks preceeding entry (n = 3). The 
characteristics of the 62 evaluable patients are shown in 
Table 2. No statistically significant differences were apparent 
between the groups with regard to age, diagnosis, number of 
previous pregnancies, and history of previous transfusions.
P ro toco l Violations
During the study period, pooled leukocyte-depleted (fil­
tered) random multiple-donor platelet concentrates were by 
error administered on 14 occasions: 8 transfusions into 6 
patients in the standard group; 6 transfusions into 4 patients
in the filtered group. Of these 10 patients, 3 became refrae-
Table2. Platelet Products
Standard
Group
Filtered
Group
No. of products 347 324
No. of platelets (x10#) 352 ± 94 302 :± 102
No. of leukocytes (x10a) 430 ± 703 2 :± 3
No. of product with leukocytes:
< 2  x 10® 0 (0%)** 159 (52%)
2-5 x 10® 3 (1%) 133 (44%)
6-10 x 10“ 1 (.3%) 7 (2%)
11-20 X 10« 7 (2%) 3 (1%)
>20 x  106 317 (97%) 1 (.3%)
ND 19 21
H M
No, of platelets and leukocytes are expressed as mean ± SD. Values 
in parentheses represent the percentage of counted products. 
Abbreviation: ND, not determined.
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Fig 1, Kaplan-Meier life table plot of frequency 
and rate of refractoriness as a function of time (A) 
or number of platelet transfusions (B) and anti-HLA 
antibody formation as a function of time (C) or num­
ber of platelet transfusions (D). Ordinate: proportion 
of patients not becoming refractory (A, B) and pro­
portion of patients not forming anti-HLA antibodies 
(C, D). (—), Filtered group; (— ), standard group.
tory after this protocol violation: 2 patients in the standard 
group and 1 patient in the filtered group. Exclusion of these 
patients from analysis from the moment of receiving a ran­
dom multiple-donor transfusion would not have altered the 
outcome of the analysis (data not shown).
Eight patients in the filtered group received a total number 
of 11 platelet products containing greater than 5 X 106 leuko­
cytes. Two of these patients became refractory. The number 
of leukocytes in the four transfusions administered to these 
two patients varied from 5.1 X 106 to 7.0 X 106 leukocytes 
with the exception of one transfusion containing 20 X 106 
leukocytes.
Development o f  Refractoriness and HLA-Alloimmunization
Refractoriness. In this study, 671 random single-donor 
transfusions were administered during the study period in 
both groups. Recovery data were available in 592/671 (88%) 
transfusions at 1 hour and in 576/671 (86%) transfusions at 
16 to 20 hours posttransfusion. In 643/671 transfusions
of refractoriness and the time interval to develop refractori­
ness. When the patients in the filtered group were censored 
from the moment of receiving a platelet product containing 
more than 5 X 106 leukocytes, the difference between the 
two groups was also not statistically significant (log-rank P 
= .32). With the Cox proportional hazard model, using the 
number of days until refractoriness or until the last transfu­
sion as time variable, the relative risk of becoming refractory 
in the filtered group as compared with the standard group 
was 0.75 (95% CL: 0.31, 1.8). This corresponds to a 9% 
reduction in the actuarial probability of becoming refractory
(95% CL: -21% , +31%).
HLA-alloimmunization. From 55 of the 62 evaluable pa­
tients, sera were available and tested for the presence of 
anti-HLA antibodies. In 9 o f these 55 patients, anti-HLA 
antibodies were present in the serum obtained at entry and 
these patients were not evaluable for the occurrence of sero­
conversion. The results of the analysis regarding the occur­
rence of seroconversion in the remaning 46 patients are
(96%), the 1- or the 16-hour recovery measurement was shown in Fig 1, C and D. Anti-HLA antibodies developed
*  fa. A  » A  M '  *  *  ^  M  m  ^  _  m
available. in 9/21 (43%) of patients receiving filtered platelets and in
Twenty-two of 62 (35%) patients became refractory to 11/25 (44%) of patients receiving standard platelets. There
random single-donor platelet transfusions. The judgement of were no statistically sign ificant differences in both incidence
refractoriness was established as follows: (1) in 17 patients, of anti-HLA antibodies and time to develop anti-HLA anti-
1 -hour posttransfusion platelet recoveries of less than 20% bodies (log-rank P -  .41). The relative risk of developing
occurred on at least two successive occasions; in 3 of these anti-HLA antibodies in the filtered group as compared with
patients, nonimmunologic factors known to decrease platelet the standard group was 1.5 (95% CL: 0.6, 3.7). This corre-
recovery (temperature >38.5°C: n = 2, DIC: n = 1) were sponds to an increase in the actuarial probability of devel-
present; in the sera of these 3 patients, anti-HLA antibodies oping anti-HLA antibodies of 14% (95% CL: -16% , +42%,
were demonstrable. (2) in five patients, a 1-hour posttransfu- Cox proportional hazard model). With regard to the reactiv-
sion platelet recovery of less than 20% occurred once in the ity pattern of the anti-HLA antibodies, the median percentage
presence of anti-HLA antibodies. panel reactive antibodies (PRA) at the time of seroconver-
In Fig 1, A and B, the development of refractoriness for sion in the filtered group was 24% (range, 10 to 67) and in
the two groups is shown. In the standard group, 14/34 (41%) the standard group 43% (range, 10 to 100). This difference
patients became refractory, versus 8/28 (29%) patients in was statistically not significant (P =  .65, Mann-Whitney U
the filtered group. Actuarial analysis using the log rank test test). Sera contained multispecific anti-HLA antibodies with
showed that this difference was not statistically significant the exception of sera from five patients in which HLA-speci-
(P  =  .52). This type of analysis includes both the incidence ficities were identified. Sera of four patients in the filtered
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group showed HLA specificities: anti-B5 (10% PRA); anti- 
B7 (24% PRA); anti-A2 + B44 (67% PRA); and anti-A3 +  
B5 (19% PRA). In the standard group, only in one patient 
anti-Al was identified (52% PRA).
Of the 22 refractory patients, five were considered refrac­
tory because a single transfusion failure was associated with 
the presence of anti-HLA antibodies. Fifteen of the re­
maining 17 refractory patients were evaluable for anti-HLA 
antibodies: in 13 of these 15 (87%), anti-HLA antibodies 
were detected. In 35 of the 40 nonrefractory patients, the 
presence of anti-HLA antibodies could be evaluated: in 11 of 
these 35 patients (31%), anti-HLA antibodies were detected.
DISCUSSION
The present study shows that in patients with previous 
pregnancies, leukocyte depletion of random single-donor 
platelet transfusions to less than 5 X I O'1 leukocytes per 
transfusion does not reduce the incidence of platelet refracto­
riness and anti-HLA antibodies. In »40%  of the patients 
studied, anti-HLA alloantibodies developed irrespective of 
whether platelet products were leukocyte depleted or not.
There are several arguments indicating that in the majority 
of patients the development of anti-HLA antibodies resulted 
from a secondary anti-HLA immune response. Firstly, the 
frequency of 40% HLA-alloimmunization after transfusion 
of filtered blood products observed in this study is much 
higher than has been found in patients at risk for primary 
HLA-alloimmunization of whom only 11 % developed anti- 
HLA antibodies after leukocyte-depleted transfusions.11 Sec­
ondly, it has been shown that 40% of females in second or 
further pregnancy develop anti-HLA antibodies,18*19 which transfusion of blood containing leukocytes sharing at least
the case, although it cannot be excluded that small numbers 
of leukocytes that were below detection level have been 
present in the transfusion products used in these studies. To 
test this hypothesis, further studies are needed with blood 
products containing even less contaminating leukocytes, eg, 
less than 104 per transfusion. Such a study would require both 
the availability of new blood filters with increased leukocyte 
removal capacity that are currently being developed21 and 
also the development of methods that allow enumeration of 
the very low number of leukocytes remaining postfiltration, 
eg, by PCR.
Also based on animal studies, soluble HLA-antigens or 
microparticles escaping leukocyte filtration may evoke plate­
let refractoriness.22,2'' In humans, Pellegrino et al24 found that
transfusion of plasma that contains leukocyte fragments from 
selected donors resulted in the onset of anti-HLA antibodies. 
As our patients received blood products that contained 
plasma, it cannot be excluded that this might have had a role 
in the stimulation of anti-HLA antibodies.
Another approach to reduce secondary HLA-alloimmuni­
zation is the use of UV-irradiation of blood products. Prelim­
inary data from animal and clinical studies suggest that UV 
irradiation might reduce primary HLA-alloimmunization, 
while in vitro data suggest that the secondary immune re­
sponse may be prevented.25,26 It was suggested in animal 
studies that UV-B irradation is superior to leukocyte deple­
tion in the prevention of the immune response.27
Finally, it might be worthwile to explore strategies based 
on other mechanisms to modify the immune response. Stud­
ies in renal transplantation patients have shown that the
is in close agreement with the frequency of anti-HLA anti­
bodies found in this study. Thirdly, in both study groups, 
anti-HLA antibodies occurred in 50% of the alloimmunized 
patients within 2 weeks o f the first transfusion. This is con­
siderably faster than in primary HLA-
one HLA-DR antigen between donor and recipient results in
reduced incidence of primary t 
by a state of immune unres 
transfusions.28 Whether thismis mate
zation
where this took a median o f 8 to 16 weeks for patients 
receiving filtered platelet products (< 5  X 10f>
and a median of 4 weeks for patients in the control group 
(mean number of leukocytes, 35 X 106).11
Previous studies have identified women with pregancies 
as patients with an increased risk for HLA-alloimmunization. 
When leukocyte-depleted platelet transfusions, which con­
tain, on average, 46 X l(V’ leukocytes, were administered, 6 
of 8 patients with previous pregnancies became refractory 
versus none of 17 nonpresensitized patients.20 Previously, it 
had been shown that platelet transfusions containing less 
than 20 X I O'1 leukocytes induced refractoriness in 15 of 71 
(21%) of females with previous pregnancies, whereas this 
occurred in only 16 of 264 (6%) nonpresensitized patients.1(1 
In the present study, leukocyte depletion was more vigourous 
and we have now shown that platelet products containing 
less than 5 X 10° leukocytes (mean, 2 X H)'1) do not result 
in a reduction of the frequency of refractoriness and HLA- 
alloimmunization nor in the time required to become refrac­
tory or develop HLA-alloimmunization.
An explanation for this finding may be that platelets per
ss to further 
menon could
be applied for the prevention of a secondary immune re­
sponse remains to be elucidated.
In conclusion, it is now well established that primary 
HLA-alloimmunization caused by transfusions of RBCs and 
platelets can be prevented when the number of leukocytes 
is reduced below the threshold for alloimmunization by leu­
kocyte depletion of the blood products. Although the number 
of leukocytes that will lead to a primary immune response 
is not precisely known, presently available blood bank tech­
nology, especially filtration, will allow the routine prepara­
tion of blood products with a degree of leukocyte depletion 
sufficient to prevent primary HLA-alloimmunization. A sub­
group of patients now remains for whom the use of leuko­
cyte-depleted transfusions does not reduce the incidence of 
alloimmunization, ie, women with previous pregnancies. 
Hence, future studies dealing with the prevention of transfu­
sion-induced HLA-alloimmunization should focus on this 
category of patients.
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